1. HTTP://FACULTY.KSU.EDU.SA/ADEL_ALMOGREN/DEFAULT.ASPX Dr. Adel Al-Mogren 1

2. B.Sc Clinical Laboratory Sciences from King Saud University, Dept. of Clinical Laboratory Sciences, February 1994. M.Sc. Molecular and Tumor Immunology from State University of New York at Buffalo, Department of Clinical Laboratory Sciences, September 1999, for thesis entitled “Peptide Mimicry to a tumor associated antigen: Galb1-3 GalNAc through the use of phage display library”. Ph.D. Clinical Immunology and Immunodiagnostics from University of Dundee, Department of Molecular and Cellular Pathology, April 2003, for thesis entitled “Structural and Functional analysis of Different Forms of IgA1 and IgA2 purified from Human Serum or Colostrum”. Examined by Prof. Brian Sutton, King's College London. almogren@ksu.edu.sa 2

3. The Discovery The aim. The antibody. The vaccine. Funds and rewards. 3

4. 4 King Abdullah

5. 5 the primary breast tumor was extracted by a little mastectomy on the mouse. One group was treated with the (TF-AG) antibody, and left the other group untreated. Different results. Resulting, with (TF-Ag) binding to vascular endothelium, it is jamming a primary metastatic step and providing a survival advantage.

6. 6 For more information:  http://lujainshatha.wikispaces.com/ http://lujainshatha.wikispaces.com/

7. LUJAIN AL-SHRAIM 431202001 SHATHA ALTAHAN 431200977 Done By: 7